Investigating Potential of Personalized Biomarkers in Redefining Treatment Response in Patients with Glioblastoma using Multiparametric MRI and Liquid Biopsy
Enrolling By Invitation
99 years and younger
All
Phase
N/A
30 participants needed
1 Location
Brief description of study
This study aims to investigate 30 patients with a diagnosis of Glioblastoma to develop a decision support system by incorporating advanced MR imaging, liquid biopsy, and MGMT promoter status to determine with higher accuracy whether tumor changes are true progression or pseudo progression. Analysis of these results will hopefully have a major impact on precision diagnostics in clinical management of GBM patients, creating personalized therapeutics.
Eligibility of study
You may be eligible for this study if you meet the following criteria:
- Conditions: Medical Research
-
Age: - 99 Years
-
Gender: All
Updated on
04 Oct 2024.
Study ID: 834159
If you need assistance finding a non-cancer clinical research study or if you have any questions, please email psom-ocr@pobox.upenn.edu
For cancer trials contact EmergingMed: 1-855-216-0098 or PennCancerTrials@emergingmend.com
